Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Regulatory News In Brief

This article was originally published in The Gray Sheet

Executive Summary

HHS newborn screening panel: Recommendation that all newborns be screened for 29 rare medical conditions will be discussed when the Advisory Committee on Heritable Disorders & Genetic Diseases in Newborn & Children convenes April 21-22 in Washington, D.C. A report elucidating the proposed recommendations will be published the week of Feb. 28 in the Federal Register, with comments due the week of May 1. The committee has dropped a test for G6PD deficiency from the recommended test panel, citing insufficient evidence to justify screening (1"The Gray Sheet" Sept. 27, 2004, p. 6)...

You may also be interested in...

Expanded Newborn Screening Recommended By HHS Advisory Committee

HHS is one step closer to establishing national guidelines advising which tests should be added to state-mandated newborn screening programs

Sarepta Scores Another Remarkable Approval With Vyondys 53 For Duchenne

Formal dispute resolution was key element in four-month turnaround from rejection by US FDA to approval for golodirsen, the second Sarepta DMD drug to clear the agency after appearing to have minimal prospects.

Real-World Evidence Fails Another Test At US FDA

Correvio’s attempt to move vernakalant from 'clinical hold' to 'FDA approved' was a huge long shot. But the advisory committee vote – and looming FDA rejection – are another indication that real-world data is not a panacea.




Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts